Quantcast

Latest adenosine Stories

2009-01-29 09:36:08

Brain cells called astrocytes help to cause the urge to sleep that comes with prolonged wakefulness, according to a study in mice, funded by the National Institutes of Health. The cells release adenosine, a chemical known to have sleep-inducing effects that are inhibited by caffeine."Millions of Americans suffer from disorders that prevent a full night's sleep, and others "“ from pilots to combat soldiers "“ have jobs where sleepiness is a hazard. This research could lead to...

2009-01-29 08:22:52

Scientists have discovered an unexpected brain mechanism that modulates the regulation of sleep and the consequences of sleep deprivation. The research, published by Cell Press in the January 29th issue of the journal Neuron, opens new avenues for development of treatments for disorders and cognitive deficits associated with sleep loss.Glial cells are brain cells that do not transmit nerve impulses the way that neurons do. Astrocytes are a type of glial cell that play multiple supportive...

2008-11-11 09:00:47

HemoBioTech, Inc. (OTCBB: HMB) (www.hemobiotech.com) announced today that Dr. Arthur P. Bollon, its Chairman & CEO, will make a company presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on November 12, at 12 noon. The meeting will be held at The New York Palace Hotel in New York City. The conference is a leading health care conference involving venture capital and investment banking firms and analysts specializing in health care. Dr. Bollon will review the...

2008-09-17 21:00:20

By Lydia Gehring During a change of routine many people change their intake of caffeinated beverages. They may miss their morning coffee or perhaps increase their intake of caffeinated soda pops. Getting a headache or becoming irritable in the morning after missing a morning cup of tea or coffee could signal a caffeine addiction reaction. This is a fact because I just spent four days away from home and had a headache on Day No. 3. I sought out a cup of hot tea and after leaving the tea...

2008-08-12 09:01:36

LA JOLLA, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (BULLETIN BOARD: DSKA) ("Duska") announced today that it has received comments from the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products on a synopsis of a proposed Phase 3 clinical study with its lead drug, ATPace(TM), for the acute treatment of a frequent cardiac arrhythmia called paroxysmal supraventricular tachycardia (PSVT). On April 16, 2008, Duska met with the...

2008-08-05 06:00:46

Clinical Data, Inc. (NASDAQ:CLDA) today announced the acquisition of Adenosine Therapeutics, L.L.C., a developer of drug products based on its extensive portfolio of composition of matter and method of use patents relating to selective adenosine receptor modulators. In exchange for all of the company's operating assets, Clinical Data paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate $3.2 million, 32-month promissory note. Contingent...

2008-07-25 09:00:33

SCHAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia -- a potentially life-threatening irregular heart beat. Sagent's amiodarone HCl injection will be available immediately in 150 mg/3...

2008-07-23 09:01:21

LA JOLLA, Calif., July 23 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (BULLETIN BOARD: DSKA) ("Duska") announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products. Based on recent communications with the FDA, including a face-to-face meeting held on April 16, 2008, Duska believes that the proposed single,...

2008-06-24 09:01:41

DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability of Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide MPI -- a test that detects and characterizes coronary artery disease -- in patients unable to undergo adequate exercise stress. Lexiscan, co-developed with CV Therapeutics , is the first A2A adenosine receptor agonist shown to be safe and effective as a...

2008-06-18 15:00:45

Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S. Food and Drug Administration to advance INO-8875 into clinical trials. The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients. Glaucoma patients typically have...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related